Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Alan S. Coates, Andrew Tutt, Binghe Xu et al.|Annals of Oncology|2015Cited by 1.8k
Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination TrialMitch Dowsett, Aman U. Buzdar, Craig Allred et al.|Journal of Clinical Oncology|2008Cited by 464
Use of Coronary Computed Tomographic Angiography to Guide Management of Patients With Coronary DiseaseMichelle C. Williams, David E. Newby, Amanda Hunter et al.|Journal of the American College of Cardiology|2016Cited by 341
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month resultsRobert E. Coleman, Nigel Bundred, Richard de Boer et al.|Annals of Oncology|2012Cited by 337
Burdens and Benefits of Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil and Tamoxifen for Elderly Patients With Breast Cancer: The International Breast Cancer Study Group Trial VIIDiana Crivellari, Marco Bonetti, Monica Castiglione‐Gertsch et al.|Journal of Clinical Oncology|2000Cited by 295